Drug development for chronic cancers: time to think differently?
- PMID: 22987092
- DOI: 10.1200/JCO.2012.42.3269
Drug development for chronic cancers: time to think differently?
Comment in
-
Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?J Clin Oncol. 2013 Jun 20;31(18):2362. doi: 10.1200/JCO.2012.47.7927. Epub 2013 May 13. J Clin Oncol. 2013. PMID: 23669225 No abstract available.
-
Reply to M.L. Friedlander et al.J Clin Oncol. 2013 Jun 20;31(18):2363. doi: 10.1200/JCO.2012.48.3743. J Clin Oncol. 2013. PMID: 23930276 No abstract available.
Comment on
-
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17. J Clin Oncol. 2012. PMID: 22987083 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
